Anaphylaxis clinical trials

Explore recruiting anaphylaxis clinical trials.

Recruiting anaphylaxis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Anaphylaxis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Exploratory study to assess the pharmacokinetic interaction of doxepin with adrenaline after a concomitant co-administration using the Anapen® device and to compare the adrenaline comparative bioavailability with Anapen®500 commercial form in healthy normal weight male subjects

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

An open-label, crossover trial in otherwise healthy volunteers with allergic rhinitis to evaluate the relative bioavailability and hemodynamic effects of OX640 nasal epinephrine powder to a marketed epinephrine intramuscular injection

Sweden

Human Pharmacology (Phase I)- Other EU CTIS Study details

A bioavailability study of epinephrine following a single dose of emergency response auto-injector in comparison to epinephrine injection into muscle via syringe in healthy adults.

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

The use of dupilumab in treatment of indolent systemic mastocytosis with skin involvement

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II Open-Label Pilot Trial Assessing the Safety of Anifrolumab in Adult Patients with Primary Antiphospholipid Syndrome (APS). The AnifAPS trial.

Greece

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase III, Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Prophylaxis in Patients with Type 3 Von Willebrand Disease

Belgium, Sweden, Spain, Germany, France, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Anaphylaxis trials by city

Anaphylaxis in Toronto Anaphylaxis in Vancouver Anaphylaxis in Montreal Anaphylaxis in Calgary Anaphylaxis in Edmonton Anaphylaxis in Ottawa Anaphylaxis in Winnipeg Anaphylaxis in Quebec City Anaphylaxis in Hamilton Anaphylaxis in Kitchener Anaphylaxis in London Anaphylaxis in Halifax Anaphylaxis in New York Anaphylaxis in Los Angeles Anaphylaxis in Chicago Anaphylaxis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease